创模生物科技(北京)有限公司

CN / En

NEWS

What is unique about the InnoModels Biotechnology CDX platform?

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-08 14:45
  • Views:

(Summary description)In the vast field of biomedical research and clinical treatment, the innovation and development of modeling platforms are crucial for advancing scientific research, accelerating the development of new drugs, and realizing personalized treatment. Against this backdrop, InnoModels Biotechnology (Beijing) Co., Ltd. has become a leader in the industry with its unique CDX (Cancer-Derived Xenograft) platform. In this article, we will discuss the unique features of the CDX platform and how it provides strong support for cancer research and clinical treatment.

What is unique about the InnoModels Biotechnology CDX platform?

(Summary description)In the vast field of biomedical research and clinical treatment, the innovation and development of modeling platforms are crucial for advancing scientific research, accelerating the development of new drugs, and realizing personalized treatment. Against this backdrop, InnoModels Biotechnology (Beijing) Co., Ltd. has become a leader in the industry with its unique CDX (Cancer-Derived Xenograft) platform. In this article, we will discuss the unique features of the CDX platform and how it provides strong support for cancer research and clinical treatment.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-08 14:45
  • Views:
Information

In the vast field of biomedical research and clinical treatment, the innovation and development of modeling platforms are crucial for advancing scientific research, accelerating the development of new drugs, and realizing personalized treatment. Against this backdrop, InnoModels Biotechnology (Beijing) Co., Ltd. has become a leader in the industry with its unique CDX (Cancer-Derived Xenograft) platform. In this article, we will discuss the unique features of the CDX platform and how it provides strong support for cancer research and clinical treatment.
1. Huge tumor cell line library
The first and foremost unique feature of the InnoModels CDX platform is its large tumor cell line library. The platform has over 400 different tumor cell lines covering a wide range of cancer types and subtypes. This diverse collection provides researchers with an extremely rich set of options, ensuring that they are able to select the most appropriate cell lines for their research, thus ensuring the relevance and efficacy of their studies. This large resource library provides powerful data support for cancer research and helps researchers gain a deeper understanding of the complexity and diversity of cancer.
2. Rich Experimental Experience and Technical Support
Another unique feature of InnoModels' CDX platform is its rich experimental experience and technical support. The platform consists of a team of experienced experts who have more than 10 years of experience in the field of CDX modeling. From experienced researchers and QC specialists to project managers, the shared knowledge among the team members ensures the smooth execution of the project. They not only understand the complexities of CDX modeling, but also provide valuable insights into the design and implementation of projects. In addition, the platform is equipped with a variety of advanced inoculation and delivery technologies, such as subcutaneous inoculation, bilateral inoculation (lysovirus), in situ inoculation, etc., as well as multiple routes of delivery, such as i.t (injection into tumor tissue), i.v (intravenous), etc., in order to satisfy the needs of different studies.

 


3. Strict quality control process and research team
InnoModels' CDX platform attaches great importance to the integrity and compliance of experimental data. They adopt a strict QC process to ensure that all cells are tested for STR (Short Tandem Repeat) and Mycoplasma and Chlamydia to ensure the purity and quality of the cells. In addition, they are committed to performing RNAseq or other similar tests on the selected cells to ensure that the mutations and expression of the desired targets are as expected. In terms of the scientific team, the InnoModels Biotechnology CDX platform is led by PhDs with extensive industry experience who are committed to providing scientific support for each project. Whether it's guidance on experimental design, problem solving, or data interpretation, the team of experts ensures that research projects run smoothly.
4. Advanced in vivo imaging and in situ inoculation technology
InnoModels Biotechnology CDX platform also adopts advanced in vivo imaging and in situ inoculation technologies. With the firefly luciferase (Luc)-labeled CDX model, researchers can perform in situ inoculation with in vivo imaging monitoring. This technology helps researchers observe tumor growth and metastasis, as well as drug distribution and efficacy in the body in real time. In addition, in situ inoculation technology can also more accurately simulate the growth environment of tumors in the human body, providing a more clinically relevant experimental platform for drug development and personalized treatment.
5. High portability and wide application prospects
One of the major advantages of InnoModels' CDX platform is its high portability. By transplanting the patient's cancer tissues into mice and other animals to form human-derived xenograft tumors, CDX technology retains the heterogeneity and complexity of the original tumor tissues. This makes the CDX model highly applicable in drug development. Researchers can use this model to systematically evaluate the effects of different drugs on tumors and accelerate the process of new drug development. In addition, CDX technology is widely used in the research of various cancer types, such as breast cancer, lung cancer, colorectal cancer, etc., providing a universal tool for interdisciplinary cancer research.
In conclusion, with its unique features such as a large tumor cell line library, rich experimental experience and technical support, strict quality control process and research team, advanced in vivo imaging and in situ inoculation technology, as well as high portability and wide application prospects, the InnoModels Biotechnology CDX platform has demonstrated a strong competitiveness in the field of cancer research and clinical treatment. In the future, with the continuous development and innovation of the technology, the InnoModels Biotechnology CDX platform is expected to provide more effective treatment solutions for cancer patients and make greater contributions to human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司